215 related articles for article (PubMed ID: 16385755)
1. New drug policy in childhood obesity.
Molnár D
Int J Obes (Lond); 2005 Sep; 29 Suppl 2():S62-5. PubMed ID: 16385755
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacotherapy in the treatment of obesity].
Hamann A
MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
[TBL] [Abstract][Full Text] [Related]
4. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study.
Viner RM; Hsia Y; Neubert A; Wong IC
Br J Clin Pharmacol; 2009 Dec; 68(6):844-51. PubMed ID: 20002078
[TBL] [Abstract][Full Text] [Related]
5. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
6. Modern medical management of obesity: the role of pharmaceutical intervention.
Aronne LJ
J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
[TBL] [Abstract][Full Text] [Related]
7. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
[TBL] [Abstract][Full Text] [Related]
8. Orlistat for obesity.
Med Lett Drugs Ther; 1999 Jun; 41(1055):55-6. PubMed ID: 10436767
[No Abstract] [Full Text] [Related]
9. [Anti-obesity drugs: sibutramine and orlistat].
Sempere I Verdú E; Palop Larrea V; Hidalgo Mora JJ; Martínez-Mir I
Med Clin (Barc); 2002 Mar; 118(11):437; author reply 437-8. PubMed ID: 11943108
[No Abstract] [Full Text] [Related]
10. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
[TBL] [Abstract][Full Text] [Related]
11. [Drug treatment of obesity].
Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
García Díaz E; Martín Folgueras T
Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
[TBL] [Abstract][Full Text] [Related]
13. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety.
Glazer G
Arch Intern Med; 2001 Aug 13-27; 161(15):1814-24. PubMed ID: 11493122
[TBL] [Abstract][Full Text] [Related]
14. Incorrect use of orlistat and sibutramine in clinical practice.
Dahlin A; Beermann B
Eur J Clin Pharmacol; 2007 Feb; 63(2):205-9. PubMed ID: 17205321
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
Halford JC
Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy of obesity: an update.
Schurgin S; Siegel RD
Nutr Clin Care; 2003; 6(1):27-37. PubMed ID: 12841428
[TBL] [Abstract][Full Text] [Related]
17. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
Richter WO
MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for obesity.
Halford JC
Appetite; 2006 Jan; 46(1):6-10. PubMed ID: 16229924
[TBL] [Abstract][Full Text] [Related]
19. Obesity, cardiovascular risk and pharmacotherapy.
Ruilope LM; Garcia-Robles R; Moreno B
Blood Press; 2002; 11(5):260-2. PubMed ID: 12458647
[No Abstract] [Full Text] [Related]
20. [New treatments for obesity].
Féry F; Watrin I
Rev Med Brux; 1999 Sep; 20(4):A381-5. PubMed ID: 10523928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
